Endocrine oncology

Clinicopathological Findings of 220 Pediatric, Adolescent, and Young Adult Patients with Thyroid Cancer in Fukushima Medical University Hospital

ThyroidPublished Descriptive study

Authors' conclusion

The pathological findings of the detected thyroid cancers indicated that the majority were classical papillary carcinomas, and approximately half of the patients had extrathyroidal or lymphovascular invasion. No differences were observed between the two age groups in terms of the clinical or pathological characteristics of thyroid cancer.

Study context

Population
Pediatric, adolescent and young adult patients with cytologically diagnosed thyroid cancer referred from the Fukushima Health Management Survey thyroid US examinations, treated at Fukushima Medical University Hospital (as of September 2021)of 263 diagnosed
Participants
220 participants
Outcome
Clinicopathological characteristics
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Age at diagnosis, median (IQR)
18.6 (16.2-20.3) years
Maximum tumor diameter, median
13.0 (10.4-18.0) mm
Unilateral lobectomy
199 (90.1%)
Papillary thyroid carcinomas (PTC)
216 (98.2%)
PTC of classical type
205
Stage I disease
216 (98.2%)
Extension into sternothyroid muscle or perithyroidal soft tissues
112 (50.9%)
Microscopic lymphovascular invasion
123 (55.9%)

Further findings

Clinical or pathological characteristics by age group (<18.6 years vs ≥18.6 years)

No differences between the two age groups; risk classification
P = 0.69
No differences between the two age groups; ATA pediatric risk level
P = 0.24

Original publication

Clinicopathological Findings of 220 Pediatric, Adolescent, and Young Adult Patients with Thyroid Cancer in Fukushima Medical University Hospital. Thyroid. Published 14 October 2024. doi:10.1089/thy.2024.0226

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.